Citations

Clear

2391 citation(s) found for "Ma, Lin".

Characteristics of Clinical Trial Sites for Novel Transcatheter Mitral and Tricuspid Valvular Therapies
Nathan, Ashwin S. , Reddy, Kriyana P. , Yang, Lin , Dayoub, Elias J. , Julien, Howard , Szeto, Wilson Y. , Kobayashi, Taisei , Fiorilli, Paul N. , Batchelor, Wayne , Giri, Jay , Kobayashi, Taisei J , Eberly, Lauren A. , Khatana, Sameed Ahmed M. , Desai, Nimesh D. , Herrmann, Howard C. , Mehran, Roxana , Alkhouli, Mohamad , Groeneveld, Peter W , Fanaroff, Alexander C.

Mayo Clinic

JAMA Cardiology | December 7, 2022 | Volume: 8 | Issue: 2 | Pages: 120

10.1001/jamacardio.2022.4457 | PMID 36477493 Get It

ImportanceRacial and ethnic minority and socioeconomically disadvantaged patients have been underrepresented in randomized clinical trials. Efforts have focused on enhancing inclusion of minority groups at sites participating at clinical trials; however, there may be differences in the patient populations of the sites that participate in clinical trials.ObjectiveTo identify any differences in the racial, ethnic, and socioeconomic composition of patient populations among candidate sites in the US that did vs did not participate in trials for novel transcatheter therapies.Design, Setting, and ParticipantsThis cross-sectional analysis used Medicare Provider Claims from 2019 for patients admitted to hospitals in the US. All clinical trials for transcatheter mitral and tricuspid valve therapies and the hospitals participating in each of the trials were identified using ClinicalTrials.gov. Hospitals with active cardiac surgical programs that did not participate in the trials were also identified. Data analysis was performed between July 2021 and July 2022.ExposuresMultivariable linear regression models were used to identify differences in racial, ethnic, and socioeconomic characteristics among patients undergoing cardiac surgery or transcatheter aortic valve replacement at trial vs nontrial hospitals.Main Outcome and MeasuresThe main outcome of the study was participation in a clinical trial for novel transcatheter mitral or tricuspid valve therapies.ResultsA total of 1050 hospitals with cardiac surgery programs were identified, of which 121 (11.5%) participated in trials for transcatheter mitral or tricuspid therapies. Patients treated in trial hospitals had a higher median zip code–based household income (difference of $5261; 95% CI, $2986-$7537), a lower Distressed Communities Index score (difference of 5.37; 95% CI, 2.59-8.15), and no significant difference in the proportion of patients dual eligible for Medicaid (difference of 0.86; 95% CI, −2.38 to 0.66). After adjusting for each of the socioeconomic indicators separately, there was less than 1% difference in the proportion of Black and Hispanic patients cared for at hospitals participating vs not participating in clinical trials.Conclusions and RelevanceIn this cohort study among candidate hospitals for clinical trials for transcatheter mitral or tricuspid valve therapies, trial hospitals took care of a more socioeconomically advantaged population than nontrial hospitals, with a similar proportion of Black and Hispanic patients. These data suggest that site selection efforts may improve enrollment of socioeconomically disadvantaged patients but may not improve the enrollment of Black and Hispanic patients.
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology
Dutta, Ankit K. , Alberge, Jean-Baptiste , Lightbody, Elizabeth D. , Boehner, Cody J. , Dunford, Andrew , Sklavenitis‐Pistofidis, Romanos , Mouhieddine, Tarek H. , Cowan, Annie , Su, Nang Kham , Horowitz, Erica , Barr, Hadley , Hevenor, Laura , Perry, Jacqueline , Cao, Amanda , Lin, Ziao , Kuhr, Frank K. , Mastro, Richard G. Del , Greipp, Patricia T. , Auclair, Daniel , Ghobrial, Irene M. , Cowan, Annie N , Horowitz, Erica M , Beckwith, Jenna B , Perry, Jacqueline , Cao, Amanda , Lin, Ziao , Kuhr, Frank K , Mastro, Richard G Del , Nadeem, Omar , Greipp, Patricia T , Stewart, Chip , Auclair, Daniel , Getz, Gad , Ghobrial, Irene M , Sklavenitis-Pistofidis, Romanos , Su, Nang K , Alberge, Jean-Baptiste , Nadeem, Omar , Getz, Gad

Mayo Clinic

Cancer Discovery | December 7, 2022 | Volume: 13 | Issue: 2 | Pages: 348-363

10.1158/2159-8290.cd-22-0482 | PMID 36477267 Get It

Abstract Multiple myeloma (MM) develops from well-defined precursor stages; however, invasive bone marrow (BM) biopsy limits screening and monitoring strategies for patients. We enumerated circulating tumor cells (CTC) from 261 patients (84 monoclonal gammopathy of undetermined significance, 155 smoldering multiple myeloma, and 22 MM), with neoplastic cells detected in 84%. We developed a novel approach, MinimuMM-seq, which enables the detection of translocations and copy-number abnormalities through whole-genome sequencing of highly pure CTCs. Application to CTCs in a cohort of 51 patients, 24 with paired BM, was able to detect 100% of clinically reported BM biopsy events and could replace molecular cytogenetics for diagnostic yield and risk classification. Longitudinal sampling of CTCs in 8 patients revealed major clones could be tracked in the blood, with clonal evolution and shifting dynamics of subclones over time. Our findings provide proof of concept that CTC detection and genomic profiling could be used clinically for monitoring and managing disease in MM. Significance: In this study, we established an approach enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics. CTCs harbored the same pathognomonic MM abnormalities as BM plasma cells. Longitudinal sampling of serial CTCs was able to track clonal dynamics over time and detect the emergence of high-risk genetic subclones. This article is highlighted in the In This Issue feature, p. 247
Abstract PR008: Evaluation of intra-tumoral pathogenic bacteria pks+ E. coli, enterotoxigenic B. fragilis and fusobacterium nucleatum in 3695 colorectal cancer cases
Hullar, Meredith A.J. , Curtis, Keith R. , Steinfelder, Robert S. , Berndt, Sonja I. , Figueiredo, Jane C. , French, Amy J. , Goode, Ellen L. , Thibideau, Stephen N., Phipps, Amanda I. , Peters, Ulrike , Harrison, Tabitha A. , Lin, Yi , Buchanan, Daniel D. , Chan, Andrew T. , Drew, David, Jenkins, Mark A. , Melaku, Yohannes Adama , Moreno, Vı́ctor , Ogino, Shuji

Mayo Clinic

Cancer Research | December 2, 2022 | Volume: 82 | Issue: 23_Supplement_1 | Pages: PR008-PR008

10.1158/1538-7445.crc22-pr008 Get It

Abstract Background: The microbiome in colorectal cancer (CRC) tumors is now recognized as a potent facilitator of tumorigenesis. Identification of the intra-tumoral microbiome may provide an avenue to enhance prediction of adverse outcomes and ultimately lead to improved survival of CRC, the second leading cause of cancer death. Methods: We performed targeted sequencing of tumor and matched normal DNA samples for 3695 colorectal cancer cases within the Genetics and Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR). Tumor DNA was extracted primarily from formalin fixed paraffin embedded (FFPE) or from fresh frozen tissue. FFPE slides were dissected to ensure >70% tumor content. Normal DNA was primarily extracted from blood and otherwise normal surrounding colorectal tissue. We designed probes for bacterial pathogens including Bacteroides fragilis (ETBF), polyketide synthase positive E. coli (pks+ EC), enterotoxigenic and Fusobacterium nucleatum (Fn). Logistic regression was used to assess tumor-associated bacteria and various clinical parameters, tumor molecular characteristics, and tumor stage adjusted for age, sex, and study and a Cox promotional hazard to assess association with CRC-specific survival adjusted for age at diagnosis, sex, mutational burden and microsatellite instability (MSI) and stratified baseline hazards by study. Survival data were available for 2357 patients. Results: The prevalence of patients with bacteria in tumors varied for ETBF (5.2%), pks+ EC (12.9%), and Fn (10.4%). Men had a lower probability of tumors with Fn (odds ratio (OR)=0.8, 95% confidence interval (CI)=0.64-0.99,p=0.04) but higher odds of tumors with pks+ EC (OR=1.38, CI=1.14-1.68,p=0.001). Patients with proximal tumors had higher odds of carrying Fn (OR=1.76, CI=1.38-2.26, p<0.001) as did patients with MSI high tumors (OR 2.79, CI=2.08-3.74) p<0.001). Patients with MSI-high tumors had lower odds of carrying pks+ EC (OR=0.63, CI=0.44-0.88, p=0.008) when compared to patients with microsatellite stable tumors. Among non-hypermutated tumors, we observed that tumors positive for pks+ EC were associated with better CRC-specific survival (OR=0.73, CI=0.57-0.93,p=0.01 whereas in patients with ETBF positive tumors had shorter survival (OR=1.99,CI=1,18-3.36,p=0.009) as did patients with tumors positive for Fn (OR=1.33, CI=1.04-1.72, p=0.03). Conclusions: In this largest investigation of intra-tumoral bacteria in CRC, we demonstrate that inclusion of pathogenic intra-tumoral microbiome may enhance prediction of survival and can identify a subset of patients with CRC that may benefit from targeted therapies that modulate the tumor microbiome. Citation Format: Meredith A. J. Hullar, Keith R. Curtis, Tabitha A. Harrison, Yi Lin, Robert S. Steinfelder, Sonja I. Berndt, Daniel D. Buchanan, Andrew T. Chan, David Drew, Jane C. Figueiredo, Amy J. French, Ellen L. Goode, Mark A. Jenkins, Yohannes A. Melaku, Victor Moreno, Shuji Ogino, Stephen N. Thibideau, Amanda I. Phipps, Ulrike Peters. Evaluation of intra-tumoral pathogenic bacteria pks+ E. coli, enterotoxigenic B. fragilis and fusobacterium nucleatum in 3695 colorectal cancer cases [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1):Abstract nr PR008.
Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease
Jambeau, Mélanie, Meyer, Kevin D. , Tabet, Ricardos, Lee, Chao-Zong , Ray-Soni, Ananya, Aguilar, Corey, Savage, Kitty, Mishra, Nibha, Cavegn, Nicole, Borter, Petra, Lin, Chun-Chia , Jansen‐West, Karen , Freyermuth, Fernande, Pérez‐Berlanga, Manuela , Jiang, Xin, Daughrity, Lilian M., Pereira, João D. , Narayanan, Sarav, Gu, Yuanzheng , Dhokai, Shekhar, Dalkilic-Liddle, Isin, Maniecka, Zuzanna, Weber, Julien, McAlonis‐Downes, Melissa , Berezovski, Eugene, Zhang, Yong-Jie, Wainger, Brian J. , Kankel, Mark W. , Rushe, Mia, Höck, Christoph, Nitsch, Roger M., Cleveland, Don W. , Petrucelli, Leonard , Polymenidou, Magdalini , Lagier‐Tourenne, Clotilde , Zhang, Yong‐Jie , Zhang, Yong-Jie , Lagier-Tourenne, Clotilde , Jiang, Xin , Zhang, Yong-Jie , Hruška-Plocháň, Marián , Ray-Soni, Ananya, Mishra, Nibha, Li, Nan , Rossi, Pierre De , Daughrity, Lilian M., Workman, Michael J. , Berry, James D. , Gendron, Tania F. , Montrasio, Fabio , Grimm, Jan

Mayo Clinic

Proceedings of the National Academy of Sciences | December 1, 2022 | Volume: 119 | Issue: 49 | Pages: No page available

10.1073/pnas.2123487119 | PMID 36454749 Get It

Hexanucleotide G 4 C 2 repeat expansions in the C9orf72 gene are the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Dipeptide repeat proteins (DPRs) generated by translation of repeat-containing RNAs show toxic effects in vivo as well as in vitro and are key targets for therapeutic intervention. We generated human antibodies that bind DPRs with high affinity and specificity. Anti-GA antibodies engaged extra- and intra-cellular poly-GA and reduced aggregate formation in a poly-GA overexpressing human cell line. However, antibody treatment in human neuronal cultures synthesizing exogenous poly-GA resulted in the formation of large extracellular immune complexes and did not affect accumulation of intracellular poly-GA aggregates. Treatment with antibodies was also shown to directly alter the morphological and biochemical properties of poly-GA and to shift poly-GA/antibody complexes to more rapidly sedimenting ones. These alterations were not observed with poly-GP and have important implications for accurate measurement of poly-GA levels including the need to evaluate all centrifugation fractions and disrupt the interaction between treatment antibodies and poly-GA by denaturation. Targeting poly-GA and poly-GP in two mouse models expressing G 4 C 2 repeats by systemic antibody delivery for up to 16 mo was well-tolerated and led to measurable brain penetration of antibodies. Long-term treatment with anti-GA antibodies produced improvement in an open-field movement test in aged C9orf72 450 mice. However, chronic administration of anti-GA antibodies in AAV-(G 4 C 2 ) 149 mice was associated with increased levels of poly-GA detected by immunoassay and did not significantly reduce poly-GA aggregates or alleviate disease progression in this model.
The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
Albanyan, Omar , Iacoboni, Gloria , Mohty, Razan , Dreyling, Martin, Lin, Yi , Subklewe, Marion , Rejeski, Kai , Wang, Yucai , Muñoz, Javier , Sesques, Pierre , López‐Corral, Lucía , Locke, Frederick L. , Barba, Pere , Bachy, Emmanuel , Jain, Michael D.

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 651-653

10.1182/blood-2022-167329 Get It

Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
Bansal, Radhika , Khurana, Arushi , Jankowski, Matthew, Hathcock, Matthew , Hampel, Paul J. , Ansell, Stephen M. , Johnston, Patrick B. , Lin, Yi , Bennani, N. Nora , Paludo, Jonas , Wang, Yucai , Durani, Urshila

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9504-9505

10.1182/blood-2022-167622 Get It

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis
Abonour, Rafat , Gibbs, Sarah N. , Finkel, Muriel , Landau, Heather , Lentzsch, Suzanne , Lin, Grace , Mahindra, Anuj, Quock, Tiffany P. , Rosenbaum, Cara A. , Rosenzweig, Michael , Yermilov, Irina , Broder, Michael S. , Gertz, Morie A. , Sidana, Surbhi , Tuchman, Sascha Alexander , Witteles, Ronald

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 13129-13131

10.1182/blood-2022-156832 Get It

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
Murray, David , Kapoor, Prashant , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L., Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Claveau, Jean‐Sébastien , Dispenzieri, Angela , Binder, Moritz , Buadi, Francis K. , Dingli, David , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2347-2348

10.1182/blood-2022-167430 Get It

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML
Johnson, Mary Ann , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Foran, James M. , Baer, Maria R. , Kovacsovics, Tibor , Olin, Rebecca L. , Blum, William , Schiller, Gary J. , Redner, Robert L. , Al‐Mansour, Zeina , Curran, Emily , Heerema, Nyla A. , Martycz, Molly , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Druggan, Franchesca , Burd, Amy , Borate, Uma , Byrd, John C. , Byrd, John C , Zeidner, Joshua F. , Foster, Matthew C , Johnson, Mary, Stock, Wendy , Madanat, Yazan F. , Lin, Tara L. , Chen, Timothy Frank , Levine, Ross L. , Druker, Brian J , Mims, Alice S

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9070-9073

10.1182/blood-2022-166715 Get It

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Munshi, Nikhil C. , Martin, Thomas G. , Usmani, Saad Z. , Lin, Yi , Schecter, Jordan M. , Jackson, Carolyn C. , Zudaire, Enrique, Yeh, Tzu‐Min, Bartlett, J. Blake , Pacaud, Lida , Geng, Dong , Usmani, Saad , Paiva, Bruno , Madduri, Deepu , Akram, Muhammad , Jagannath, Sundar , Cohen, Adam D. , Miguel, Jesús F. San

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4652-4654

10.1182/blood-2022-159141 Get It